JUN 21, 2018 07:30 AM PDT

Keynote Presentation: Paving the Path Towards Precision Medicine in Inflammatory Bowel Diseases

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Director of Translational Research, Crohn's & Colitis Foundation
    Biography
      Dr. Andrés Hurtado-Lorenzo is the Senior Director of Translational Research at the Crohn's and Colitis Foundation. He is responsible for planning and oversight the Foundation's translational research portfolio that consist of a number research initiatives in the fields of: Precision Medicine, Genetics, Microbiome, Environmental Triggers, and Entrepreneurial Investing, a venture philanthropy initiative focused on accelerating product development in IBD. These initiatives aim to identify opportunities to translate observations in the laboratory and clinic into interventions that reach and benefit patients; from therapeutics and diagnostics to medical devices and procedures.

      Dr. Hurtado-Lorenzo is a translational scientist leader with previous proven success directing multidisciplinary teams focused on drug discovery and development for neurological diseases and rare diseases in the biotech and pharmaceutical industry (Wyeth, Pfizer, Proteostasis Therapeutics) from discovery to early clinical development. These efforts have resulted in the identification of candidate drugs currently evaluated in clinical trials.

      He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he pioneered work in the field of viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease. His research has been published in books high impact factor publications like Nature Cell Biology and Nature Communications.

    Abstract:

    Crohn’s disease and ulcerative colitis also known as inflammatory bowel diseases or IBD, are characterized by chronic, recurrent inflammation of the gastrointestinal tract, which results from the interplay between genetic predisposition, altered immune response, intestinal microbial dysbiosis and environmental factors. The course of the disease is variable, with some patients having much more aggressive disease than others. Half of the patients will develop severe complications like strictures, fistulas and abscesses, which require surgery. In addition, some patients experience frequent relapses while others achieve prolonged remission without any additional therapy. Such variability in prognosis represents the difference between an excellent long-term outcome or progressive disability. Therefore, the main challenge in managing IBD is the early detection, ideally at diagnosis, of patients with potentially severe disease course and variability in treatment outcomes. Thus, if precision medicine is to be applied in IBD, it will require the stratification of patients with a high risk of relapse and complications, and better characterization of patients who may respond preferentially to specific therapies. In this presentation I will highlight current advances towards the integration of clinical and molecular phenotypes for early prediction of complicated disease course at diagnosis and response to biological therapy. I will also highlight the current efforts of the Crohn’s and Colitis Foundation to build the largest biorepository and research exchange platform called IBD Plexus, which aims to integrate longitudinal clinical data and patient reported outcomes from than 40,000 patients along with genetic and multi-omics profiles from 7,000 IBD patients, and how this platform will accelerate the path towards precision medicine in IBD.


    Show Resources
    Loading Comments...